Zobrazeno 1 - 10
of 101
pro vyhledávání: '"Carrolee, Barlow"'
Autor:
Stefanie Lerche, Isabel Wurster, Enza Maria Valente, Micol Avenali, Daniela Samaniego, Marta Martínez-Vicente, Jorge Hernández-Vara, Ariadna Laguna, Andrea Sturchio, Per Svenningsson, Nicholas P. France, Carrolee Barlow, Sethu Sankaranarayanan, Kathrin Brockmann
Publikováno v:
npj Parkinson's Disease, Vol 10, Iss 1, Pp 1-6 (2024)
Abstract Variants in GBA1 result in dysregulated sphingolipids. We investigated five CSF d18:1 sphingolipid species in a longitudinal multicenter cohort comprising people with Parkinson’s Disease and Dementia with Lewy bodies with and without GBA1
Externí odkaz:
https://doaj.org/article/0432f15037794f51a76f397dcdb3ce10
Autor:
Nicholas Pena, Tara Richbourg, Claudia P. Gonzalez-Hunt, Rui Qi, Paul Wren, Carrolee Barlow, Natalie F. Shanks, Holly J. Carlisle, Laurie H. Sanders
Publikováno v:
npj Parkinson's Disease, Vol 10, Iss 1, Pp 1-15 (2024)
Abstract Pathogenic mutations in LRRK2 cause Parkinson’s disease (PD). The G2019S variant is the most common, which results in abnormally high kinase activity. Compounds that target LRRK2 kinase activity are currently being developed and tested in
Externí odkaz:
https://doaj.org/article/04c86851f418476ba1a0c1df027d9486
Autor:
Nicholas P. France, Christopher Rubino, M. Courtney Safir, Mari Maurer, Tram Duong, Deepika Singamsetty, Khalid Abd‐Elaziz, Thomas Chou, Sethu Sankaranarayanan, Marieke Ettema, Rebecca Cosford, Peter Dogterom, Enchi Liu, Carrolee Barlow
Publikováno v:
Clinical Pharmacology in Drug Development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2df720e85f402bd4d993ab5caeaa059
https://doi.org/10.1002/cpdd.1256
https://doi.org/10.1002/cpdd.1256
Autor:
Nicholas Pena, Claudia P. Gonzalez-Hunt, Rui Qi, Carrolee Barlow, Natalie F. Shanks, Holly J. Carlisle, Laurie H. Sanders
Pathogenic mutations inLRRK2cause Parkinson’s disease (PD). The G2019S variant is the most common, which results in abnormally high kinase activity. Compounds that target LRRK2 kinase activity are currently being developed and tested in clinical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef34efb569ccbffc275d271bc1d31bc5
https://doi.org/10.1101/2022.11.30.517979
https://doi.org/10.1101/2022.11.30.517979
Autor:
Mesude Bicak, Georgina E. Perez‐Garcia, Jacqueline Buros, Jean‐Vianney Haure‐Mirande, Gissel E. Perez, Alena Otero‐Pagan, Miguel E. Gama‐Sosa, Rita E. DeGasperi, Mary Sano, Fred H. Gage, Carrolee Barlow, Joel Dudley, Benjamin S. Glicksberg, Yanzhuang Wang, Benjamin Readhead, Michelle E. Ehrlich, Gregory A. Elder, Sam Gandy
Publikováno v:
Alzheimer's & Dementia. 18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::577a5c9ef3ba31ef4a38fa30f7fb6240
https://doi.org/10.1002/alz.062751
https://doi.org/10.1002/alz.062751
Autor:
Tyler P. Molitor, Enchi Liu, Alyssa M. A. Toda, Kristin M. Andruska, Molly Murphy, Paul Wren, Jessica M. Bright, Holly J. Carlisle, Carrolee Barlow
Publikováno v:
Movement Disorders
Background A common genetic mutation that causes Parkinson's disease (PD) is the G2019S LRRK2 mutation. A precision medicine approach that selectively blocks only excess kinase activity of the mutant allele could yield a safe and effective treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed6d2a9bbbc45b4e28d085fae888ae77
https://doi.org/10.1002/mds.28490
https://doi.org/10.1002/mds.28490
Autor:
Georgina Perez-Garcia, Mesude Bicak, Jacqueline Buros, Jean-Vianney Haure-Mirande, Gissel M. Perez, Alena Otero-Pagan, Miguel A. Gama Sosa, Rita De Gasperi, Mary Sano, Fred H. Gage, Carrolee Barlow, Joel T. Dudley, Benjamin S. Glicksberg, Yanzhuang Wang, Benjamin Readhead, Michelle E. Ehrlich, Gregory A. Elder, Sam Gandy
Modulation of physical activity represents an important intervention that may delay, slow, or prevent mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease (AD). One mechanism proposed to underlie the beneficial effect of physical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ecf9b941bcbebe4bcbe8c225bdbd101
https://doi.org/10.1101/2022.01.31.477906
https://doi.org/10.1101/2022.01.31.477906
Autor:
Georgina Perez-Garcia, Mesude Bicak, Jean-Vianney Haure-Mirande, Gissel M. Perez, Alena Otero-Pagan, Miguel A. Gama Sosa, Rita De Gasperi, Mary Sano, Carrolee Barlow, Fred H. Gage, Benjamin Readhead, Michelle E. Ehrlich, Sam Gandy, Gregory A. Elder
Publikováno v:
Neuroscience Letters. 797:137080
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6dc95c5abcabe5d5a3766e5f4854af8
https://doi.org/10.1016/j.neulet.2023.137080
https://doi.org/10.1016/j.neulet.2023.137080
Autor:
David G Warnock, Daniel G Bichet, Myrl Holida, Ozlem Goker-Alpan, Kathy Nicholls, Mark Thomas, Francois Eyskens, Suma Shankar, Mathews Adera, Sheela Sitaraman, Richie Khanna, John J Flanagan, Brandon A Wustman, Jay Barth, Carrolee Barlow, Kenneth J Valenzano, David J Lockhart, Pol Boudes, Franklin K Johnson
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134341 (2015)
Migalastat HCl (AT1001, 1-Deoxygalactonojirimycin) is an investigational pharmacological chaperone for the treatment of α-galactosidase A (α-Gal A) deficiency, which leads to Fabry disease, an X-linked, lysosomal storage disorder. The currently app
Externí odkaz:
https://doaj.org/article/f26e7d47b7944128ad874cc4db71fb8b
Publikováno v:
Parkinsonism & Related Disorders. 44:33-37
Background Gastrointestinal symptoms, such as dysphagia, postprandial bloating, and defecatory straining are common in Parkinson's Disease (PD) and they impact quality of life. Endoscopic botulinum neurotoxin (BoNT) injection has been used in the tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b74b04aac849b545f7f6782c03a30f7c
https://doi.org/10.1016/j.parkreldis.2017.08.020
https://doi.org/10.1016/j.parkreldis.2017.08.020